{
    "id": 28253,
    "fullName": "EZH2 Y646H",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "EZH2 Y646H (corresponds to Y641H in the canonical isoform) lies within a SET domain of the Ezh2 protein (UniProt.org). Y646H is predicted to confer a gain of function to the Ezh2 protein, as demonstrated by altered substrate specificity and increased catalytic efficiency for H3K27 trimethylation (PMID: 21078963).",
            "references": [
                {
                    "id": 2703,
                    "pubMedId": 21078963,
                    "title": "Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21078963"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2146,
        "geneSymbol": "EZH2",
        "terms": [
            "EZH2",
            "ENX-1",
            "ENX1",
            "EZH2b",
            "KMT6",
            "KMT6A",
            "WVS",
            "WVS2"
        ]
    },
    "variant": "Y646H",
    "createDate": "05/13/2018",
    "updateDate": "09/17/2018",
    "referenceTranscriptCoordinates": {
        "id": 175970,
        "transcript": "NM_004456",
        "gDna": "chr7:g.148811636A>G",
        "cDna": "c.1936T>C",
        "protein": "p.Y646H",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 6950,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in partial response for more than 16 weeks in a non-Hodgkin lymphoma patient harboring a EZH2 Y646H mutation (ASH 57th Annual Meeting and Exposition, Dec 2015, Abstract #473; NCT01897571).",
            "molecularProfile": {
                "id": 29842,
                "profileName": "EZH2 Y646H"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 60060,
                "name": "non-Hodgkin lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5984,
                    "pubMedId": null,
                    "title": "Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients",
                    "url": "http://www.bloodjournal.org/content/126/23/473?sso-checked=true"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19564,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Tazemetostat (EPZ-6438) treatment resulted in a durable partial response in a patient with diffuse large B-cell lymphoma harboring EZH2 Y646H, and the patient was progression-free for 16 months (PMID: 29650362; NCT01897571).",
            "molecularProfile": {
                "id": 29842,
                "profileName": "EZH2 Y646H"
            },
            "therapy": {
                "id": 2683,
                "therapyName": "Tazemetostat",
                "synonyms": null
            },
            "indication": {
                "id": 50745,
                "name": "diffuse large B-cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17176,
                    "pubMedId": 29650362,
                    "title": "Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29650362"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 29842,
            "profileName": "EZH2 Y646H",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 175970,
            "transcript": "NM_004456",
            "gDna": "chr7:g.148811636A>G",
            "cDna": "c.1936T>C",
            "protein": "p.Y646H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 175971,
            "transcript": "XM_011515884",
            "gDna": "chr7:g.148811636A>G",
            "cDna": "c.1936T>C",
            "protein": "p.Y646H",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}